This clinical trial investigates a treatment for recurrent metastatic nasopharyngeal carcinoma, a type of cancer that starts in the nasopharynx (the upper part of the throat behind the nose) and has spread to other parts of the body or has come back after previous treatment. The study evaluates a combination therapy using toripalimab (a type of immunotherapy drug) together with gemcitabine and cisplatin chemotherapy as a first treatment for patients whose cancer cannot be treated with local therapies.
The main purpose of this study is to understand how safe this combination treatment is by monitoring serious side effects that may occur during therapy. The treatment involves receiving the medications through intravenous infusion. The study will track how patients respond to the treatment and measure both the time until the cancer might progress and overall survival.
The study will include adult patients who have measurable cancer that can be seen on imaging scans and who have not received previous systemic therapy for their recurrent or metastatic disease. Patients must have confirmation of their Epstein-Barr virus status and be in relatively good physical condition to participate.
Italy 
